Recent preclinical data demonstrated the synergistic effect of combining HER2 blockade with immune checkpoint inhibition, that is, HER2 blockade by the antibody-drug conjugate trastuzumab-emtansine, leading to an improved PD-1 and CTLA4 blockade in an orthotopic breast cancer model (20). Here, ERBB2 is linked to breast cancer.